A small open-label trial gave patients with active ulcerative colitis oral TUDCA for six weeks and measured endoscopic and histologic change. What it found, and the four reasons the result needs a controlled trial before it means much.
PBC is the one condition where TUDCA has been tested head-to-head against standard-of-care UDCA in a randomized trial. Here is what those human studies found, and why that does not make TUDCA a substitute for prescription treatment.
Bloating, greasy stools, discomfort after fatty meals – is this a bile acid deficiency, and does TUDCA help? An honest look at what the research actually covers.
TUDCA is well studied for inherited retinal degeneration. Does the evidence support it for age-related macular degeneration specifically? An honest look at the RPE research.
TUDCA and kidney function: what the animal research on acute kidney injury, diabetic nephropathy, and ER stress shows, and why human trials don’t exist yet.
What the research on TUDCA and bile acid physiology actually shows for people managing gallbladder disease or recovering after cholecystectomy.
A review of preclinical evidence on TUDCA and photoreceptor protection in retinal degeneration, including proposed mechanisms and animal model findings.
A plain-language review of the preclinical evidence for TUDCA in Parkinson’s disease, covering dopamine neuron protection, mitochondria, and research limits.
An evidence-based look at how TUDCA may influence ER stress, insulin sensitivity, and fat cell biology in obesity and metabolic syndrome research.
An evidence-based look at how TUDCA may protect neurons, the mechanisms proposed by researchers, and where human evidence stands today.
A science-based look at how TUDCA may affect NAFLD and NASH through bile acid regulation, ER stress, and gut-liver axis mechanisms.
TUDCA blocks Bax-driven cytochrome c release and Bad activation to inhibit mitochondrial apoptosis. Here is what the research shows.